Laurent Servais

Liege, WAL, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 250 publications

Evidence no longer matters: newborn screening in England.

Evidence no longer matters: newborn screening in England.

Journal: Lancet (London, England)

Published: July 29, 2026

Reopening the Silk Road for rare neurological diseases.

Reopening the Silk Road for rare neurological diseases.

Journal: European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society

Published: July 29, 2026

A Validated Prognostic Score for Time to Loss of Ambulation in Patients With Duchenne Muscular Dystrophy.

A Validated Prognostic Score for Time to Loss of Ambulation in Patients With Duchenne Muscular Dystrophy.

Journal: Neurology

Published: May 26, 2026

In response to: Personalized antioxidant supplementation improves muscle strength, physical activity, and quality of life in patients with FSHD1: A real-world longitudinal study. Laoudj-Chenivesse D, Arbogast S, Raynaud De Mauverger E, Fedou C, Debroize E, Hugon G, Pincemail J, Picot MC, Cristol JP, Mercier J, Portet F. Free Radic Biol Med. 2026 Feb 28; 248: 424-435.

In response to: Personalized antioxidant supplementation improves muscle strength, physical activity, and quality of life in patients with FSHD1: A real-world longitudinal study. Laoudj-Chenivesse D, Arbogast S, Raynaud De Mauverger E, Fedou C, Debroize E, Hugon G, Pincemail J, Picot MC, Cristol JP, Mercier J, Portet F. Free Radic Biol Med. 2026 Feb 28; 248: 424-435.

Journal: Free radical biology & medicine

Published: April 26, 2026

Genomic newborn screening for actionable, sight-threatening eye diseases.

Genomic newborn screening for actionable, sight-threatening eye diseases.

Journal: Canadian journal of ophthalmology. Journal canadien d'ophtalmologie

Published: March 31, 2026

Corrigendum to "Learnings from a registry-based cohort study for spinal muscular atrophy disease" [Neuromuscular Disorders, Volume 59, February 2026, 106332].

Corrigendum to "Learnings from a registry-based cohort study for spinal muscular atrophy disease" [Neuromuscular Disorders, Volume 59, February 2026, 106332].

Journal: Neuromuscular disorders : NMD

Published: March 28, 2026

Emerging Therapies for Angelman Syndrome.

Emerging Therapies for Angelman Syndrome.

Journal: CNS drugs

Published: February 17, 2026

To screen or not to screen G6PD deficiency in gNBS: insights from the BabyDetect pilot and current evidence.

To screen or not to screen G6PD deficiency in gNBS: insights from the BabyDetect pilot and current evidence.

Journal: European journal of human genetics : EJHG

Published: January 30, 2026

Efficacy and safety of risdiplam in patients with type 1 spinal muscular atrophy: a 3-year open-label extension of the two-part, phase 2 FIREFISH trial.

Efficacy and safety of risdiplam in patients with type 1 spinal muscular atrophy: a 3-year open-label extension of the two-part, phase 2 FIREFISH trial.

Journal: The Lancet. Child & adolescent health

Published: January 28, 2026

Advancing treatment of spinal muscular atrophy through inhibition of the myostatin signaling pathway.

Advancing treatment of spinal muscular atrophy through inhibition of the myostatin signaling pathway.

Journal: Expert review of neurotherapeutics

Published: January 22, 2026

Broad lessons from negative trials in rare diseases.

Broad lessons from negative trials in rare diseases.

Journal: The Lancet. Neurology

Published: January 21, 2026

A novel ASCC1 splice-site variant broadens the phenotypic spectrum of spinal muscular atrophy with congenital bone fractures type 2.

A novel ASCC1 splice-site variant broadens the phenotypic spectrum of spinal muscular atrophy with congenital bone fractures type 2.

Journal: Neuromuscular disorders : NMD

Published: December 29, 2025

Showing 1-12 of 250

Last Updated: 09/26/2026